Marion Webb has been writing about medtech since 2017, specializing in covering buzzy segments such as robotic surgery, digital therapeutics and femtech with in-depth features and interviews with leading experts. Her role includes reporting live from industry events, moderating panel discussions and podcasts, tweeting breaking news and engaging KOLs to provide high-quality, business-critical content for Medtech Insight. Marion has been writing about health care issues for more than two decades. She was a long-time biotech reporter at the San Diego Business Journal, worked at Bloomberg News, and contributed to the Los Angeles County Medical Association’s Physician Magazine. Marion was born and raised in Germany, is fluent in German and conversational in Spanish. Off the job, she’s a competitive runner, avid cyclist and swimmer, and enjoys spending time with her domestic partner and her German Shorthair Pointer mix Cora.
Latest from Marion Webb
Medtech Insight spoke with Meghan Scanlon, president of Boston Scientific’s urology division, about integration plans for the recently acquired Axonics medtech. The purchase adds sacral neuromodulation to Boston Scientific’s portfolio, a global market that research reports valued at $1.6bn in 2023.
This week, the US device center announced a pilot program to speed communications about high-risk recalls; Cardinal paid $3.9B for Advanced Diabetes Supply Group and GIA Alliance; a companion diagnostic for Merck lung cancer drug Tepmetko got FDA clearance; and more.
Medtech Insight spoke with executives from Spanish medtech firm Time is Brain about their wearable device that monitors stroke victims in real time, potentially saving lives.
Abbott is celebrating the opening of its new manufacturing facility in Ireland for diabetes care.
This week, Zimmer Biomet announced a new role of chief movement officer for Arnold Schwarzenegger, J&J MedTech receives IDE approval for Ottava, Dassault Systèmes with US FDA develop first guide for virtual twins, Mainz Biomed and Thermo Fisher team up to fight colorectal cancer.
Massachusetts-based Harbinger Health has partnered with Memorial Sloan Kettering Cancer Center in New York to accelerate the validation of its AI-driven blood test for early-stage cancer detection. The company also recently presented encouraging data at two conferences.